The ezetimibe controversy: implications for clinical practice. - Wikidata - wikimedia - TriplyDB

The ezetimibe controversy: implications for clinical practice.

The ezetimibe controversy: implications for clinical practice.

http://www.wikidata.org/entity/Q37884287

about

Animal models of diabetic macrovascular complications: key players in the development of new therapeutic approaches Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs.Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia.Current drug treatment of hyperlipidemia in older adults.Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.A solid-state NMR study of amorphous ezetimibe dispersions in mesoporous silica.

P2860

Q26822630-31D4663C-BF9E-44FD-AD4E-6D4FEBF6DB8C Q36470320-1DF5D763-0064-48E8-B73B-C88F17016E0E Q36585817-229D7855-C96A-458D-A1DA-FBA42D0CBAC5 Q37620806-34CEAB35-1179-4DAE-9E3F-EC284B4B77EB Q37972314-8D06BF48-EA39-4FBD-B3E0-5EA2FB2349FB Q38338437-CD57E7D1-BB6D-4F30-BE3E-7C632D5FF643 Q40677108-2C4FDB63-53E8-4635-8952-9391807D3E9B Q41115755-0EB3DFCC-B099-42E8-93BC-8C6168619025 Q45164709-993BEA1E-7301-4105-8A3A-DA60C0BFE9BE

P2860

The ezetimibe controversy: implications for clinical practice.

http://www.wikidata.org/entity/Q37884287

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The ezetimibe controversy: implications for clinical practice.

@en

The ezetimibe controversy: implications for clinical practice.

@nl

type

label

The ezetimibe controversy: implications for clinical practice.

@en

The ezetimibe controversy: implications for clinical practice.

@nl

prefLabel

The ezetimibe controversy: implications for clinical practice.

@en

The ezetimibe controversy: implications for clinical practice.

@nl

P1433

Q37884287-DF0046D0-7F32-473E-B096-D66FC1756895

P1476

Q37884287-76535B5F-FFB0-415E-BFB1-EE794AF75E9D

P2093

Q37884287-21479934-4689-42C4-A86E-8C4C50359862

Q37884287-AE478704-38C4-48C0-B48F-8569CE115961

Q37884287-CC8E0CFA-CC31-4034-8CF3-8942B58A4430

Q37884287-FFEF1EF8-F2CD-4A11-A38E-D23055A0A759

P2860

Q37884287-06E6F3E5-A2A4-4A31-8554-ACE23069BC26

Q37884287-09042D5D-C0DD-4ACB-A745-2535CB53084D

Q37884287-095DC128-A5E4-4C0E-87AC-7E66D086E9C8

Q37884287-0DDB8954-B829-4B09-8C8D-1F1B5E9C8647

Q37884287-0DF05C95-E672-4E16-9256-F9387A9589A6

Q37884287-1316B123-167B-43B8-AA6A-13C8FDBA0BD6

Q37884287-167983DB-AF85-429B-86B7-2BE32959C8A9

Q37884287-18CFDC6B-3CD8-47BF-99FB-DCD83B3D5ED6

Q37884287-1D745EC4-A9C5-4ED9-86F6-51413589544D

Q37884287-1E0FAEB9-A58C-4841-B0E2-4A2920B113D8

P304

Q37884287-96F6EC3B-0B1D-4BB9-BD9B-FCA7560F6B0A

P31

Q37884287-080DBC5B-199A-4682-B978-CCB80940D5E1

P356

Q37884287-E097DF0D-90DC-4FE4-96A9-B40ED3CB434A

P433

Q37884287-8F87D258-8DC6-49AF-ACBD-1DB7C2657A94

P478

Q37884287-E371C5F1-E1C2-4C57-A497-1E7BF0B95C81

P577

Q37884287-1CA06A94-B93A-4F82-8E37-96F970F4A67A

P698

Q37884287-7F5E1993-06D8-4C10-805F-E53114357509

P356

1753944711410099

P1433

Therapeutic advances in cardiovascular disease

P1476

The ezetimibe controversy: implications for clinical practice.

@en

P2093

Melvyn Rubenfire

http://www.w3.org/2001/XMLSchema#string

Randolph E Regal

http://www.w3.org/2001/XMLSchema#string

Thomas Boyden

http://www.w3.org/2001/XMLSchema#string

Ujjaini Khanderia

http://www.w3.org/2001/XMLSchema#string

P2860

Simvastatin with or without ezetimibe in familial hypercholesterolemia

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Analyses of cancer data from three ezetimibe trials.

Model system for the analysis of cell surface expression of human ABCA1.

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

P304

199-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753944711410099

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21636623

http://www.w3.org/2001/XMLSchema#string